We appreciate having the opportunity to respond to the comments and concerns raised by Dr. Mynbaev and colleagues [1] . As already mentioned in the manuscript, our aim was to evaluate the effects of gelatin-thrombin matrix on postoperative adhesion formation [2] . We did not use microsurgical techniques in the present study and therefore we did not discuss the use of gelatin-thrombin matrix during microsurgical procedures.
Due to the fact that myomectomy and most ectopic pregnancy procedures are performed as a planned surgery on a schedule, it would be erroneous to consider the operations conducted in the cited articles as emergency procedures. The gelatin-thrombin matrix has been used as an alternative treatment option in the cited studies of postpartum hemorrhage [3, 4] . Despite the fact that other studies cited in the present study reported bowel obstruction associated with the use of gelatin-thrombin matrix, these studies were cited to set an example for the use of gelatin-thrombin matrix in gynecologic oncology operations and gynecologic operations [5, 6] .
As mentioned in the methods section of the manuscript, the sample size was determined on the basis of 3R (replacement-refinement-reduction) rule and in accordance with the decisions of ethics committee and not using power analysis. Furthermore, post hoc power analysis was performed for the variables that were found to be statistically significant using the demo version of PASS software v.11. The power analysis performed for four variables that showed significant difference yielded a minimum 94 % power: extent of fibrosis, 99 %; inflammation score, 99 %; inflammatory cell activity, 94 %; and SOD activity, 99 %, respectively.
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